Skip to Main Content

Author Details

Martin L Sos
University of Cologne, Faculty of Medicine and University Hospital Cologne
2005
60
37
Nevan J Krogan (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36521334Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.Eur J Cancer2023
37289018Characterizing Evolutionary Dynamics Reveals Strategies to Exhaust the Spectrum of Subclonal Resistance in EGFR-Mutant Lung Cancer.Cancer Res2023
35247925CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.Mol Cancer Ther2022
35486541Insight into Targeting Exon20 Insertion Mutations of the Epidermal Growth Factor Receptor with Wild Type-Sparing Inhibitors.J Med Chem2022
35417004Report of the First International Symposium on NUT Carcinoma.Clin Cancer Res2022
33060857The next tier of EGFR resistance mutations in lung cancer.Oncogene2021
34921211Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer.NPJ Precis Oncol2021
34535668MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I.Nat Commun2021
32436621Sorafenib and everolimus in patients with advanced solid tumors and KRAS-mutated NSCLC: A phase I trial with early pharmacodynamic FDG-PET assessment.Cancer Med2020
32018053New Approaches to SCLC Therapy: From the Laboratory to the Clinic.J Thorac Oncol2020
30605727K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.J Thorac Oncol2019
32914023Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer.JCO Precis Oncol2019
31375684MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer.Nat Commun2019
29284707Structural Alterations of MET Trigger Response to MET Kinase Inhibition in Lung Adenocarcinoma Patients.Clin Cancer Res2018
35135141Loss of G2032R Resistance Mutation Upon Chemotherapy Treatment Enables Successful Crizotinib Rechallenge in a Patient With <i>ROS1</i>-Rearranged NSCLC.JCO Precis Oncol2018
30405134Overcoming EGFR<sup>G724S</sup>-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.Nat Commun2018
28630215Mechanisms of Primary Drug Resistance in <i>FGFR1</i>-Amplified Lung Cancer.Clin Cancer Res2017
28089889MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition.Cancer Cell2017
28615362Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors.Sci Transl Med2017
28930680Systematic Kinase Inhibitor Profiling Identifies CDK9 as a Synthetic Lethal Target in NUT Midline Carcinoma.Cell Rep2017
28737478Family matters: How MYC family oncogenes impact small cell lung cancer.Cell Cycle2017
28710318Resistance Mechanisms to AZD9291 and Rociletinib-Response.Clin Cancer Res2017
27252416Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.Clin Cancer Res2016
26001148Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient.J Thorac Oncol2015
26275028Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach.J Med Chem2015
26504226Discovery and functional characterization of a neomorphic PTEN mutation.Proc Natl Acad Sci U S A2015
26102443Implementation of Amplicon Parallel Sequencing Leads to Improvement of Diagnosis and Therapy of Lung Cancer Patients.J Thorac Oncol2015
25979930Squamous cell lung cancer: from tumor genomics to cancer therapeutics.Clin Cancer Res2015
25127139Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.Cell Rep2014
23515407Characteristics of lung cancers harboring NRAS mutations.Clin Cancer Res2013
24256730K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.Nature2013
24171479Staurosporine-derived inhibitors broaden the scope of analog-sensitive kinase technology.J Am Chem Soc2013
23953109A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1.Cell2013
23773153Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design.J Med Chem2013
22266863Genetic insight and therapeutic targets in squamous-cell lung cancer.Oncogene2012
22941188Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.Nat Genet2012
23035247A framework for identification of actionable cancer genome dependencies in small cell lung cancer.Proc Natl Acad Sci U S A2012
22684217Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer.Mod Pathol2012
22912387Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.Clin Cancer Res2012
22909821AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis.EMBO J2012
21130659Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor.Bioorg Med Chem2011
22328973Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.Cancer Discov2011
21985405L1CAM protein expression is associated with poor prognosis in non-small cell lung cancer.Mol Cancer2011
21983857A crucial requirement for Hedgehog signaling in small cell lung cancer.Nat Med2011
21948233ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.Clin Cancer Res2011
21734175Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.Sci Transl Med2011
20103621Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation.Cancer Res2010
21160078Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.Sci Transl Med2010
20222733Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor.J Med Chem2010
20111714Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling.PLoS One2010
  • 1 - 50 of 60

Recommended Authors

Kimberley Avila
University of Texas Southwestern Medical Center
Career Start Year 2017
Number of shared co-authors 2
Arjan Gower
David Geffen School of Medicine at University of California at Los Angeles
Career Start Year 2014
Number of shared co-authors 2
Yang Shao
Nanjing Geneseeq Technology Inc.
Career Start Year 2012
Number of shared co-authors 0
Margaret Soucheray
J. David Gladstone Institutes
Career Start Year 2012
Number of shared co-authors 8
Victor Olivas
University of California san francisco
Career Start Year 2012
Number of shared co-authors 10
Dana S Neel
Stanford University School of Medicine
Career Start Year 2012
Number of shared co-authors 5
Siddhartha Devarakonda
Siteman Cancer Center, Washington University School of Medicine
Career Start Year 2011
Number of shared co-authors 13
Luping Lin
Incyte Research Institute, Incyte Corporation
Career Start Year 2010
Number of shared co-authors 7
Yisong Wang
Lombardi Comprehensive Cancer Center, Georgetown University
Career Start Year 2010
Number of shared co-authors 0
Vibha Raghavan
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2009
Number of shared co-authors 2
Caroline E McCoach
UCSF Helen Diller Comprehensive Cancer Center
Career Start Year 2009
Number of shared co-authors 4
Katherine R Singleton
Duke University
Career Start Year 2009
Number of shared co-authors 1
Jaya Sangodkar
University of Michigan ann arbor
Career Start Year 2008
Number of shared co-authors 6
Alexander Drilon
Memorial Sloan Kettering Cancer Center
Career Start Year 2008
Number of shared co-authors 8
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 19
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 7
Alice H Berger
Fred Hutchinson Cancer Research Center
Career Start Year 2005
Number of shared co-authors 19
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 11
Ming Li
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 1
Jonathan R Dry
Present Address: Tempus Labs Inc.
Career Start Year 2003
Number of shared co-authors 1
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 12
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 2
Trever G Bivona
University of California san francisco
Career Start Year 2002
Number of shared co-authors 15
Collin M Blakely
University of California san francisco
Career Start Year 1998
Number of shared co-authors 8
Mathew J Garnett
Wellcome Sanger Institute
Career Start Year 1998
Number of shared co-authors 11
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 25
Siraj M Ali
Foundation Medicine
Career Start Year 1995
Number of shared co-authors 7
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 4
Ultan McDermott
Wellcome Sanger Institute
Career Start Year 1993
Number of shared co-authors 10
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 12

Collaborators

Kevan M Shokat
University of California San Francisco
Co-authored papers 8
Matthew Meyerson
Broad Institute
Co-authored papers 6
Christian Grütter
Co-authored papers 5
Holger Moch
University Hospital Zurich
Co-authored papers 4
Trudy G Oliver
Duke University
Co-authored papers 4
Rameen Beroukhim
Co-authored papers 4
John D Minna
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 3
Barbara A Weir
Janssen Research and Development LLC
Co-authored papers 3
Julien Sage
Department of Pediatrics Stanford University Stanford California USA.
Co-authored papers 3
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 3
Craig H Mermel
Co-authored papers 3
Levi A Garraway
Broad Institute of Harvard and MIT
Co-authored papers 3
Prudence A Russell
St Vincent's Hospital
Co-authored papers 2
Benjamin Solomon
Peter MacCallum Cancer Centre
Co-authored papers 2
Alma L Burlingame
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 2
Marc Ladanyi
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
Michael Peyton
Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center
Co-authored papers 2
Wendy Winckler
Co-authored papers 2
J??rg Rahnenf??hrer
TU Dortmund University
Co-authored papers 2
Gavin M Wright
St. Vincent's Hospital, University of Melbourne
Co-authored papers 2
Matthias Fischer
University Children's Hospital of Cologne
Co-authored papers 2
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Co-authored papers 2
John T Poirier
Laura and Isaac Perlmutter Cancer Center
Co-authored papers 2
William R Sellers
Co-authored papers 2
Peter S Hammerman
Novartis Institutes for BioMedical Research
Co-authored papers 2
Scott L Carter
Co-authored papers 2
Gregory J Riely
Memorial Sloan Kettering Cancer Center
Co-authored papers 1
John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
Co-authored papers 1
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 1
Alex H Ramos
Co-authored papers 1
Release 1.2